Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge.
Novo Nordisk (CPSE:NOVO B) shocked the market with first quarter 2026 results, as its new oral Wegovy weight loss pill quickly surpassed 2 million US prescriptions and prompted a higher full year outlook.
See our latest analysis for Novo Nordisk.
The strong first quarter has triggered a sharp rebound in sentiment, with a 25.69% 1 month share price return and 8.54% 7 day gain. However, the year to date share price return of 10.52% and 1 year total shareholder return of 27.91% still point to a longer period of pressure.
If this surge in GLP 1 interest has you looking beyond a single stock, it could be a moment to look for other healthcare focused AI opportunities using the 121 healthcare AI stocks.
With earnings, guidance and sentiment all moving quickly, the key question now is whether Novo Nordisk’s recent share price rebound leaves the stock undervalued, or if the market is already pricing in years of future GLP 1 growth.
Most Popular Narrative: 65.3% Undervalued
Tokyo’s widely followed narrative values Novo Nordisk at DKK851.04 per share, well above the last close at DKK295.5, which frames a sizable valuation gap.
With the unexpected success of its obesity drugs, the company has effectively gained a highly profitable new business segment almost for free, built on the same scientific platform. This windfall is now driving massive capital inflows, which Novo Nordisk is wisely reinvesting to secure its leadership for decades to come.
Curious what financial engine is behind that valuation gap? This narrative leans on robust revenue expansion, firm margins and a richer future earnings multiple to justify its fair value.
Result: Fair Value of DKK851.04 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, you still need to watch for regulatory pushback on obesity treatments, along with any slowdown in GLP 1 momentum that could challenge the long term growth story.
Find out about the key risks to this Novo Nordisk narrative.
Next Steps
With sentiment split between risks and rewards, this is the moment to review the key data for yourself and move quickly to shape your own view with the 3 key rewards and 5 important warning signs
Looking for more investment ideas?
If you stop with one stock, you could miss opportunities that better match your goals, so put the Simply Wall Street Screener to work for you today.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NOVO-B.CO.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com